Table 1 Clinical characteristics of the 70 patients included in the study

Gender (male)

31 (64.5 %)

15 (68.2 %)

0.77

Age (years)

61.2 ± 11.4

60.6 ± 11.8

0.86

BUN (mmol/L)

6.0 ± 1.5

6.1 ± 1.2

0.84

Cr (μmol/L)

76.3 ± 15.8

77.1 ± 15.2

0.82

FBG (mmol/L)

5.0 ± 0.9

5.1 ± 0.8

0.79

TC (mmol/L)

4.8 ± 0.6

4.7 ± 0.7

0.83

LVEF (%)

59.8 ± 6.4

58.7 ± 6.5

0.87

β2 agonist use

45 (93.8 %)

20 (90.9 %)

1.00

Anticholinergic use

40 (83.3 %)

19 (86.4 %)

1.00

Hormone replacement therapy

36 (75.0 %)

17 (77.3 %)

0.84

Calcium antagonist use

15 (31.2 %)

10 (45.5 %)

0.25

Amiodarone use

5 (10.4 %)

15 (68.2 %)

<0.05

Smoker

10 (20.8 %)

6 (27.3 %)

0.64

PH

7.40 ± 0.05

7.41 ± 0.08

0.13

PaO2(mmHg)

60.5 ± 5.9

59.8 ± 5.3

0.73

PaCO2(mmHg)

49.4 ± 5.6

50.5 ± 5.9

0.43

Serum K+(mmol/L)

4.2 ± 0.4

4.1 ± 0.4

0.25

Serum Na + (mmol/L)

138.8 ± 3.3

139.7 ± 3.2

0.12

Serum Cl-(mmol/L)

99.8 ± 2.0

98.8 ± 2.2

0.06

mMRC Grade 0

10 (20.8 %)

5 (22.7 %)

0.88

mMRC Grade 1

15 (31.2 %)

6 (27.3 %)

0.80

mMRC Grade 2

12 (25 %)

5 (22.7 %)

0.87

mMRC Grade 3

8 (16.7 %)

4 (18.2 %)

0.89

mMRC Grade 4

3 (6.3 %)

2 (9.1 %)

0.69